Zacks Investment Research Upgrades Q BioMed Inc (QBIO) to “Hold”
Q BioMed Inc (NASDAQ:QBIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.
According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “
Shares of Q BioMed (QBIO) opened at 3.95 on Thursday. The firm’s market cap is $41.64 million. The stock’s 50 day moving average price is $4.00 and its 200-day moving average price is $4.24. Q BioMed has a 52-week low of $2.39 and a 52-week high of $12.61.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/07/zacks-investment-research-upgrades-q-biomed-inc-qbio-to-hold.html.
Q BioMed Company Profile
Q BioMed, Inc, formerly ISMO Tech Solutions, Inc, is a biomedical acceleration and development company. The Company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company intends to acquire multiple assets over time and across a spectrum of healthcare related products, companies and sectors.
Receive News & Stock Ratings for Q BioMed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed Inc and related stocks with our FREE daily email newsletter.